Back to search resultsSummaryRMgm-4682
|
||||||||
*RMgm-4682| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene disruption |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 31634979 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei NK65 |
| Name parent line/clone | Not applicable |
| Other information parent line | |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Depoix D, Kohl L |
| Name Group/Department | CNRS Molécules de Communication et Adaptation des Micro-organismes |
| Name Institute | Muséum National d'Histoire Naturelle, Sorbonne Universités |
| City | Paris |
| Country | France |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-4682 |
| Principal name | ΔPbkin8B |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | Normal production of male and female gametocytes. No male gamete formation as shown by absence of exflagellation centers. |
| Fertilization and ookinete | Strongly reduced fertilisation and ookinete formation. In wild type parasites, the mean ookinete conversion rate as 63.5 ± 3.6, whereas it was only 1.2 ± 1.4 and 0.2± 0.2 for ΔPbkin8B clones 3600 and 3716. |
| Oocyst | Strongly reduced fertilisation and ookinete formation. In wild type parasites, the mean ookinete conversion rate as 63.5 ± 3.6, whereas it was only 1.2 ± 1.4 and 0.2± 0.2 for ΔPbkin8B clones 3600 and 3716. The two ΔPbkin8B mutant cell lines produced very few oocysts (mean range of 1.68/1.36 and 1.4/0.76 respectively) in comparison to wt and Pbkin8B-gfp parasites, where numerous oocysts were formed (mean values the 2 replicates of 180/171 and 187/160 oocysts per midgut respectively. No sporozoite formation observed in oocysts. |
| Sporozoite | The two ΔPbkin8B mutant cell lines produced very few oocysts (mean range of 1.68/1.36 and 1.4/0.76 respectively) in comparison to wt and Pbkin8B-gfp parasites, where numerous oocysts were formed (mean values the 2 replicates of 180/171 and 187/160 oocysts per midgut respectively. No sporozoite formation observed in oocysts. |
| Liver stage | No infection of mice by bite of infected mosquitoes |
| Additional remarks phenotype | Mutant/mutation Evidence is presented that: |
Disrupted: Mutant parasite with a disrupted gene| top of page | |||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_0202700 | ||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0111000 | ||||||||||||||||||||||||
| Gene product | kinesin-8B, putative | ||||||||||||||||||||||||
| Gene product: Alternative name | |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||
| Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | Yes | ||||||||||||||||||||||||
| Name of PlasmoGEM construct/vector | PbGEM-267699 | ||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||
| Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
| Additional remarks partial/complete disruption | |||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
| Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||
| Additional remarks genetic modification | |||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||
|
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||